MNMD
Price
$9.88
Change
+$1.00 (+11.26%)
Updated
Jul 21, 04:26 PM (EDT)
Capitalization
670.91M
24 days until earnings call
PGEN
Price
$1.85
Change
+$0.09 (+5.11%)
Updated
Jul 21, 04:33 PM (EDT)
Capitalization
519.52M
21 days until earnings call
Interact to see
Advertisement

MNMD vs PGEN

Header iconMNMD vs PGEN Comparison
Open Charts MNMD vs PGENBanner chart's image
Mind Medicine (MindMed)
Price$9.88
Change+$1.00 (+11.26%)
Volume$300
Capitalization670.91M
Precigen
Price$1.85
Change+$0.09 (+5.11%)
Volume$8.88K
Capitalization519.52M
MNMD vs PGEN Comparison Chart in %
Loading...
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MNMD vs. PGEN commentary
Jul 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNMD is a Hold and PGEN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 22, 2025
Stock price -- (MNMD: $8.88 vs. PGEN: $1.76)
Brand notoriety: MNMD and PGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MNMD: 101% vs. PGEN: 99%
Market capitalization -- MNMD: $670.91M vs. PGEN: $519.52M
MNMD [@Biotechnology] is valued at $670.91M. PGEN’s [@Biotechnology] market capitalization is $519.52M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNMD’s FA Score shows that 0 FA rating(s) are green whilePGEN’s FA Score has 0 green FA rating(s).

  • MNMD’s FA Score: 0 green, 5 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, MNMD is a better buy in the long-term than PGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNMD’s TA Score shows that 6 TA indicator(s) are bullish while PGEN’s TA Score has 6 bullish TA indicator(s).

  • MNMD’s TA Score: 6 bullish, 5 bearish.
  • PGEN’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, PGEN is a better buy in the short-term than MNMD.

Price Growth

MNMD (@Biotechnology) experienced а +10.17% price change this week, while PGEN (@Biotechnology) price change was -3.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.79%. For the same industry, the average monthly price growth was +16.27%, and the average quarterly price growth was +35.62%.

Reported Earning Dates

MNMD is expected to report earnings on Aug 14, 2025.

PGEN is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+2.79% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNMD($671M) has a higher market cap than PGEN($520M). PGEN YTD gains are higher at: 57.143 vs. MNMD (27.586). MNMD has higher annual earnings (EBITDA): -75.18M vs. PGEN (-154.85M). MNMD has more cash in the bank: 212M vs. PGEN (80.2M). PGEN has less debt than MNMD: PGEN (5.42M) vs MNMD (22M). PGEN has higher revenues than MNMD: PGEN (4.2M) vs MNMD (0).
MNMDPGENMNMD / PGEN
Capitalization671M520M129%
EBITDA-75.18M-154.85M49%
Gain YTD27.58657.14348%
P/E RatioN/AN/A-
Revenue04.2M-
Total Cash212M80.2M264%
Total Debt22M5.42M406%
FUNDAMENTALS RATINGS
MNMD vs PGEN: Fundamental Ratings
MNMD
PGEN
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
69
Overvalued
PROFIT vs RISK RATING
1..100
93100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
3940
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNMD's Valuation (35) in the null industry is somewhat better than the same rating for PGEN (69). This means that MNMD’s stock grew somewhat faster than PGEN’s over the last 12 months.

MNMD's Profit vs Risk Rating (93) in the null industry is in the same range as PGEN (100). This means that MNMD’s stock grew similarly to PGEN’s over the last 12 months.

MNMD's SMR Rating (97) in the null industry is in the same range as PGEN (100). This means that MNMD’s stock grew similarly to PGEN’s over the last 12 months.

MNMD's Price Growth Rating (39) in the null industry is in the same range as PGEN (40). This means that MNMD’s stock grew similarly to PGEN’s over the last 12 months.

MNMD's P/E Growth Rating (100) in the null industry is in the same range as PGEN (100). This means that MNMD’s stock grew similarly to PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MNMDPGEN
RSI
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 4 days ago
84%
Momentum
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
82%
MACD
ODDS (%)
Bullish Trend 4 days ago
89%
Bullish Trend 4 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
86%
Bearish Trend 4 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
84%
Advances
ODDS (%)
Bullish Trend 5 days ago
84%
Bullish Trend 12 days ago
84%
Declines
ODDS (%)
Bearish Trend 22 days ago
86%
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IYITX24.37N/A
N/A
Macquarie International Core Eq R
IPAYX10.89-0.01
-0.09%
Integrity Dividend Summit I
NMIEX13.10-0.02
-0.15%
Northern Active M International Equity
WSTYX72.52-0.11
-0.15%
Macquarie Science and Technology Y
TASCX19.79-0.17
-0.85%
Third Avenue Small Cap Value Instl

MNMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNMD has been loosely correlated with ATAI. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if MNMD jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNMD
1D Price
Change %
MNMD100%
N/A
ATAI - MNMD
52%
Loosely correlated
+15.77%
BEAM - MNMD
51%
Loosely correlated
+1.47%
EYPT - MNMD
51%
Loosely correlated
N/A
OCUL - MNMD
51%
Loosely correlated
-0.44%
RXRX - MNMD
51%
Loosely correlated
+5.80%
More

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with ARCT. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
-3.30%
ARCT - PGEN
47%
Loosely correlated
-0.30%
ARWR - PGEN
47%
Loosely correlated
-11.09%
XENE - PGEN
46%
Loosely correlated
N/A
BEAM - PGEN
46%
Loosely correlated
+1.47%
MNMD - PGEN
45%
Loosely correlated
N/A
More